(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 13.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.84%.
Harmony Biosciences Holdings's revenue in 2024 is $656,109,000.On average, 3 Wall Street analysts forecast HRMY's revenue for 2024 to be $40,655,598,141, with the lowest HRMY revenue forecast at $40,124,761,623, and the highest HRMY revenue forecast at $41,199,506,651. On average, 2 Wall Street analysts forecast HRMY's revenue for 2025 to be $47,996,942,153, with the lowest HRMY revenue forecast at $47,036,434,962, and the highest HRMY revenue forecast at $48,957,449,343.
In 2026, HRMY is forecast to generate $53,916,280,844 in revenue, with the lowest revenue forecast at $51,799,186,593 and the highest revenue forecast at $56,033,375,096.